During the disease course, HER2 status changed dynamically from HER2-low at initial diagnosis to HER2-0 after metastasis, and then to HER2-low again after further progression, highlighting the biological heterogeneity of metastatic breast cancer and the importance of repeat biopsy. Here, ERBB2 is linked to breast cancer.